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Pharmacokinetic Models for
Lipophilic Compounds
by H. B. Matthews,* D. B. Tuey,t and
M. W. Anderson*
In many instances pharmacokinetic modeling offers the best method ofinterpreting the significance to
man of results obtained with laboratory animals but first we must have accurate models for our labora-
tory animals. A physiological pharmacokinetic model has been used to simulate the disposition of poly-
chlorinated biphenyls (PCBs) in the rat and to extrapolate results obtained with the rat to predict the
disposition of PCBs in the ir,ouse. The modeling methods have also been extended to predict the disposi-
tion of a polybrominated biphenyl (PBB) in the rat following IV, oral, and multiple oral doses. It is
anticipated that with additional experience and work a physiological pharmacokinetic model can be used
to predict the disposition of these and other xenobiotics in man.
Introduction
Pharmacokinetics is basically a study of those
factors that determine the time concentration of a
foreign compound and its metabolites in tissue fol-
lowing a given dose. Pharmacodynamics is the
study ofthose factors which determine the relation-
ship between the concentration of a foreign com-
pound and a therapeutic or toxicological response.
Both pharmacokinetics and pharmacodynamics are
efforts to interpret the human relevance of data ob-
tained in the laboratory. Therefore, an ideal study
of a foreign compound should include both phar-
macokinetics and pharmacodynamics. However,
some environmental contaminants elicit such dif-
fuse responses as to make pharmacodynamic
studies virtually impossible. In these cases we are
restricted to studies of the pharmacokinetics of
these compounds if we are going to make any type
of accurate extrapolation from animal data to man.
This is the case with most of the halogenated hy-
drocarbons generally considered to be environmen-
tal contaminants. Therefore, we have committed
most of our effort to understanding the phar-
macokinetics of these compounds. A phar-
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macokinetic study is needed because, in most
cases, the transformation from the dosage pattern
to the concentration of the compound at the target
organ is not linear and perhaps more important the
toxicological or therapeutic response is not a func-
tion of concentration but depends upon the area
under the concentration-time curve.
We believe the most promising approach to ex-
trapolating data obtained with laboratory animals to
man is by means ofa physiological pharmacokinetic
model. A physiological pharmacokinetic model has
as its basis relevant physical and biochemical
parameters such as blood flow rates, organ sizes,
tissue binding, and metabolic rates. The model can
predict tissue levels of parent compound from vari-
ous types and patterns ofchemical exposure. Thus,
it is a simplified representation of a real biological
system derived from experimental observation,
previous knowledge, and a number ofassumptions.
A valid model for one species can be scaled to make
predictions in another species if the basic
mechanisms ofdistribution, metabolism, and excre-
tion are the same in each case.
Polychlorinated Biphenyls
We chose to study the polychlorinated biphenyls
(PCBs) because they are a major group of environ-
mental pollutants and because we think they may
serve as excellent models for the disposition of
other types of environmental pollutants.
The PCBs have been used industrially since the
October 1977 2571930's. They have been used in hydraulic fluids,
pump oils, paints, adhesives, inks, caulking com-
pounds, plastics, and a number of other products;
however, their current use is largely restricted to
the electrical industry for use in transformers and
capacitors (1). The first cases ofindustrial intoxica-
tion by PCBs were described in 1936; however, due
largely to the available technology and the fact that
the PCBs were not looked for, they were not de-
tected in the environment until 1966 (2). The first
cases of human intoxication as a result of pollution
occurred in Japan in 1968 when a large number of
persons consumed PCB-contaminated rice oil (3).
More recently, PCB contamination has raised con-
cern in the U. S. because ofthe high concentrations
in the Hudson River and the Great Lakes.
In addition to being worthy subjects of study in
their own right, the polychlorinated biphenyls are
representatives of the larger class ofenvironmental
contaminants, the halogenated hydrocarbons. This
class of compounds contains the chlorinated insec-
ticides such as DDT and Kepone, the polybromi-
nated biphenyls (PBBs), and the halogenated ben-
zenes, phenols, and naphthalenes as well as the
halogenated dioxins and furans.
One additional advantage ofstudying the PCBs is
seen from analysis of their structures. Each of the
PCBs has the same biphenyl carbon skeleton, and
they differ only in the degree and position of their
chlorination. There are 210 possible variations, and
any commercial formulation may contain 30 or
more individual chlorinated biphenyls. Since it was
obvious that we could not study them all, we have
tried to make some careful choices.
Pharmacokinetic Model
Our preliminary results indicated that a flow lim-
ited pharmacokinetic model could be used to predict
the disposition ofthe PCBs in the laboratory rat (4).
The model consists of a series of compartments
which represent particular tissues in which the con-
centration ofthe parent compounds and metabolites
are assumed to be uniform. A basic assumption of
the model is that the tissue concentrations of both
the parent compounds and the metabolites are in
equilibrium with the venous blood leaving the tis-
sue. A representative compartment of the model is
shown in Figure 1. The PCB enters the compart-
ment at one concentration in the arterial blood and
leaves it at a second concentration in the venous
blood. The concentration change is brought about
by a blood/tissue partition which is different for
each tissue. The full model is shown schematically
as a flow diagram in Figure 2. The time course of
PCB concentration is expressed by a set of differ-
ential equations which describe the individual mass
balances of both the parent compound and the
metabolites in each compartment. The model equa-
tions relate the rate of accumulation (or depletion)
of each compound in each compartment to the rate
ofinflux with arterial blood minus the rate ofefflux
with venous blood and the rate of metabolism and
excretion.
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FIGURE 1. Representation of a single compartment for a flow
limited model. From Lutz et al. (4) with permission.
FIGURE 2. Flow diagram for a pharmacokinetic model of PCB
disposition in the rat. From Lutz et al. (4) with permission.
This type of model requires knowledge of a
considerable number of biological parameters.
Where possible, the parameters were obtained from
the literature; where necessary, they were deter-
mined in our laboratory. Tine parameters used in
this model are given in Tables 1-3.
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258Table 1. Model parameters for a 250 g rat.
Blood flow,
Compartment Volume, ml ml/min
Blood 22.5
Gut lumen 14
Muscle 125 7.5
Liver 10 16
Skin 40 0.5
Fat 17.5 0.4
Table 2. Tissue to blood distribution ratios for 250 g rat.
Parent Metabolite
Compartment 1-CB 2-CB 5-CB 6-CB I-CB 2-CB 5-CB 6-CB
Blood I 1 1 1 1 1 1 I
Gut lumen 1 1 1 1 1 1 1 1
Muscle 1 2 1 4 0.14 0.40 0.10 0.30
Liver 1 3 6 12 2 5 2 4
Skin 10 10 7 30 0.25 0.30 0.10 2
Fat 30 70 70 400 0.40 0.60 0.40 2
Table 3. Kinetic parameters for a 250 g rat.a
Constants 1-CB 2-CB 5-CB 6-CB
km,ml/min
metabolism constant 10.0 2.0 0.39 0.045
kk,ml/min
kidney clearance 0.20 0.133 0.033 0.030
kB,ml/min
biliary clearance 0.20 0.35 0.30 0.30
kG, min-'
gut reabsorption 0.00016 0.00016 0.00016 0.00016
kf, min-'
fecal transport 0.0008 0.0008 0.0008 0.0008
aParameter values from Lutz etal. (4).
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Model Predictions vs.
Laboratory Data
Computer simulations using the model to predict
the distribution and excretion of PCBs by real ani-
mals are quite accurate for the slowly metabolized
PCBs in the laboratory rat. An example is given in
Figure 3, where the solid lines were generated by
the computer based on the physiological parameters
and assumptions of the pharmacokinetic model.
These lines are not curve fits of the data points
which were obtained from actual laboratory exper-
iments following a single IV dose of 2,4,5,2',4',5'-
hexachlorobiphenyl (6-CB). It should be noted that
the ordinate is a log scale and that the concentration
of 6-CB in fat and skin were much higher than in
blood.
FIGURE 3. 6-CB tissue concentrations as afunction oftime for96
hr after a single IV dose of 0.6 mg/kg in the rat. Points rep-
resent experimental data: solid lines represent computer
simulations. From Lutz et al. (4) with permission.
The distribution of 6-CB in the fat and blood at
longer periods oftime is shown in Figure 4. During
the 42-day holding period shown in Figure 4, the
body weight ofthese animals increased by approx-
imately 50%lo. Much of the increase was due to an
increase in adipose tissue. The dashed lines repre-
sent the model predictions when the tissue growth
was ignored; the solid lines represent the predic-
tions when the growth of the fat compartment was
simulated by the model.
Thus, it is seen that the model works well for this
PCB in this species. It also stimulates the distribu-
tion of all the other PCBs studied. However, this
model, like most other pharmacokinetic models,
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259works best for those compounds for which accurate
estimates ofthe in vivo metabolic rate are available.
Estimates ofthe rate ofin vivo PCB metabolism are
most accurate for those PCBs which are
metabolized most slowly. However, the lower
chlorinated PCBs, those most readily metabolized,
are the least persistent in the environment, and
human exposure is largely restricted to those PCBs
which are resistant to metabolism. This particular
hexachlorobiphenyl has been reported to be in the
highest concentration of any PCB found in human
adipose tissue (5).
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FIGURE 4. 6-CB concentration in fat and blood as a function of
time for 42 days after a single IV dose of0.6mg/kg in the rat.
Points represent experimental data; (- -) simulations with
a constant fat volume; (-) simulations with an increasing
fat volume. From Lutz et al. (4) with permission.
The idea behind studying the pharmacokinetics
of environmental contaminants is to be able to ex-
trapolate results obtained with laboratory animals
to humans. We cannot do that yet, but we have
taken the first step. We can extrapolate to mice.
Figure 5 shows a comparison ofthe computer simu-
lation and the laboratory data for the tissue distribu-
tion of this hexachlorobiphenyl in the mouse. The
solid lines represent the computer simulation; the
points represent the data obtained in the lab. Thus,
the first small step was a solid one, and the model
extrapolated to the mouse very well. We are cur-
rently in the process of obtaining the laboratory
data necessary to check our simulation of PCB dis-
tribution in the dog and the monkey. If these ex-
trapolations work as well as anticipated, we feel
confident that this model can be used to make
reasonable predictions ofthe disposition ofPCBs in
the humans.
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FIGURE 5. 6-CB tissue concentrations as a function oftime for 14
days after a single IV dose of0.6 mg/kg in the mouse. Points
represent experimental data; solid lines represent computer
simulations. From Tuey and Matthews (7).
In addition to being able to extrapolate our re-
sults obtained with the rat to other species, we
would also like to be able to extend our results ob-
tained with the PCBs to other halogenated hy-
drocarbons; and we have made a small step in that
Environmental HealthPerspectives 260direction. Figure 6 shows the results obtained when
these pharmacokinetic methods were extended to
predict the tissue concentration of a polybromi-
nated biphenyl in the rat following a single IV dose.
This particular brominated biphenyl,
2,4,5,2',4',5'-hexabromobiphenyl, is the major con-
stituent of the fire retardant, Firemaster BP-6,
which accidentally contaminated the livestock feed
and subsequently the livestock, the animal produce,
and most ofthe population of Michigan in 1973 and
1974 (6). Once again, the lines in this figure repre-
sent the computer simulation and the points repre-
sent the actual data. It is seen that the extrapolation
worked quite well.
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FIGURE 6. Hexabromobiphenyl disposition in the rat as a func-
tion of time for 42 days after a single IV dose of 1.0 mg/kg.
Points represent experimental data; solid lines represent
computer simulations. From Tuey and Matthews (8).
Since very few of us receive our environmental
contaminants via IV injection, we have studied the
disposition of multiple oral doses of the PBB and
were pleased to find that our model also accurately
predicted their disposition (Fig. 7). In Figure 7 the
lines represent the computer simulation of PBB dis-
tribution during the administration offour consecu-
tive daily doses, and the comparison with the data
obtained when rats which had received four daily
doses were sacrificed on the seventh day after the
study began. The points at day 1 represent animals
which were sacrificed 24 hr after receiving a single
oral dose. This simulation of multiple oral doses is
good, but we are currently giving the model a
tougher test by simulating the distribution of up to
30 daily doses and three different dose levels. We
are, of course, checking the simulation with actual
data obtained in the laboratory. If this simulation
and the data check out, we think we will have a
pretty good model for the PBBs.
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FIGURE 7. Hexabromobiphenyl disposition in the rat as a func-
tion oftime after 1 or 4 oral doses of 1.0mg/kg. Points repre-
sent experimental data; lines represent computer simulations.
From Tuey and Matthews (8).
Conclusions
We have demonstrated that a physiological
pharmacokinetic model can accurately simulate the
disposition of lipophilic xenobiotics in laboratory
animals. We are currently completing a model of
the disposition of Kepone in the rat, and we are
working to add the proper parameters to the model
so that it will predict the disposition of other
halogenated hydrocarbons in other species.
October 1977 261I should point out here, that we are not unaware
that if a target organ can be identified it might
necessitate additional compartments in the model to
account for the toxicity which results from a long-
term low dose exposure. This does not worry us
-the model can handle it. The only reason the
minor compartments have not been added to date is
that they account for an insignificant portion ofthe
disposition of the total dose, but they do require a
great deal of work to check.
We believe that with additional experience we
will be able to predict the disposition of a large
number of persistent xenobiotics in laboratory ani-
mals and within the next two to three years, that is,
after we have experience with afew more species, it
should be possible to begin to extrapolate some of
these results to humans.
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